Exemestane for Breast-Cancer Prevention in Postmenopausal Women | Zendy

Paul E. Goss | Zendy; James N. Ingle | Zendy; José E. AlésMartínez | Zendy; Angela M. Cheung | Zendy; Rowan T. Chlebowski | Zendy; Jean WactawskiWende | Zendy; Anne McTiernan | Zendy; John A. Robbins | Zendy; Karen Johnson | Zendy; Lisa W. Martin | Zendy; Eric Winquist | Zendy; Gloria E. Sarto | Zendy; Judy E. Garber | Zendy; Carol J. Fabian | Zendy; Pascal Pujol | Zendy; Elizabeth Maunsell | Zendy; Patricia Farmer | Zendy; Karen A. Gelmon | Zendy; Dongsheng Tu | Zendy; Harriet Richardson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Exemestane for Breast-Cancer Prevention in Postmenopausal Women

Author(s) -

Paul E. Goss,

James N. Ingle,

José E. AlésMartínez,

Angela M. Cheung,

Rowan T. Chlebowski,

Jean WactawskiWende,

Anne McTiernan,

John A. Robbins,

Karen Johnson,

Lisa W. Martin,

Eric Winquist,

Gloria E. Sarto,

Judy E. Garber,

Carol J. Fabian,

Pascal Pujol,

Elizabeth Maunsell,

Patricia Farmer,

Karen A. Gelmon,

Dongsheng Tu,

Harriet Richardson

Publication year - 2011

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1103507

Subject(s) - medicine , exemestane , breast cancer , tamoxifen , hazard ratio , raloxifene , oncology , ductal carcinoma , placebo , gynecology , cancer , confidence interval , pathology , alternative medicine

Tamoxifen and raloxifene have limited patient acceptance for primary prevention of breast cancer. Aromatase inhibitors prevent more contralateral breast cancers and cause fewer side effects than tamoxifen in patients with early-stage breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research